Skip to main content

30.09.2010 | ORIGINAL ARTICLE

Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest double-heterozygosity?

verfasst von: I.A.W. van Rijsingen, J.F. Hermans-van Ast, Y.H.J.M. Arens, S.M. Schalla, C.E.M de Die-Smulders, A. van den Wijngaard, Y.M. Pinto

Erschienen in: Netherlands Heart Journal

Einloggen, um Zugang zu erhalten

Abstract

Background. With the improvement in genetic testing over time, double-heterozygous mutations are more often found by coincidence in families with hypertrophic cardiomyopathy (HCM). Double heterozygosity can be a cause of the wellknown clinical diversity within HCM families.
Methods and results. We describe a family in which members carry either a single mutation or are double heterozygous for mutations in myosin heavy chain gene (MYH7) and cysteine and glycine-rich protein 3 (CSRP3). The described family emphasises the idea of a more severe clinical phenotype with double-heterozygous mutations. It also highlights the importance of cardiological screening where NT-proBNP may serve as an added diagnostic tool.
Conclusion. With a more severe inexplicable phenotype of HCM within a family, one should consider the possibility of double-heterozygous mutations. This implies that in such families, even when one disease-causing mutation is found, all the family members still have an implication for cardiological screening parallel to extended genetic screening. (Neth Heart J 2009;17:458–63.)
Literatur
Zurück zum Zitat Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785-9.PubMed Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785-9.PubMed
Zurück zum Zitat Maron BJ, Nichols PF, 3rd, Pickle LW, et al. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and twodimensional echocardiography. Am J Cardiol 1984;53:1087-94.CrossRefPubMed Maron BJ, Nichols PF, 3rd, Pickle LW, et al. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and twodimensional echocardiography. Am J Cardiol 1984;53:1087-94.CrossRefPubMed
Zurück zum Zitat Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003; 107:2227-32.CrossRefPubMed Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003; 107:2227-32.CrossRefPubMed
Zurück zum Zitat Van Driest SL, Ommen SR, Tajik AJ, et al. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clinic Proc. 2005;80:463-9.CrossRef Van Driest SL, Ommen SR, Tajik AJ, et al. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clinic Proc. 2005;80:463-9.CrossRef
Zurück zum Zitat Van Driest SL, Jaeger MA, Ommen SR, et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:602-10.CrossRefPubMed Van Driest SL, Jaeger MA, Ommen SR, et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:602-10.CrossRefPubMed
Zurück zum Zitat Towbin JA. Molecular genetics of hypertrophic cardiomyopathy. Curr Cardiol Reports. 2000;2:134-40.CrossRef Towbin JA. Molecular genetics of hypertrophic cardiomyopathy. Curr Cardiol Reports. 2000;2:134-40.CrossRef
Zurück zum Zitat Geier C, Perrot A, Ozcelik C, et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation. 2003;107:1390-5.CrossRefPubMed Geier C, Perrot A, Ozcelik C, et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation. 2003;107:1390-5.CrossRefPubMed
Zurück zum Zitat Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation. 2006;113:e858-62.CrossRefPubMed Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation. 2006;113:e858-62.CrossRefPubMed
Zurück zum Zitat Alders M, Jongbloed R, Deelen W, et al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003;24:1848-53.CrossRefPubMed Alders M, Jongbloed R, Deelen W, et al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003;24:1848-53.CrossRefPubMed
Zurück zum Zitat Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004; 109:2807-16.CrossRefPubMed Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004; 109:2807-16.CrossRefPubMed
Zurück zum Zitat Nguyen L, Chung J, Lam L, et al. Abnormal cardiac response to exercise in a murine model of familial hypertrophic cardiomyopathy. Int J Cardiol. 2007;119:245-8.CrossRefPubMed Nguyen L, Chung J, Lam L, et al. Abnormal cardiac response to exercise in a murine model of familial hypertrophic cardiomyopathy. Int J Cardiol. 2007;119:245-8.CrossRefPubMed
Zurück zum Zitat Tsoutsman T, Bagnall RD, Semsarian C. Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure. Clin Exp Pharmacol Physiol. 2008;35:1349-57.CrossRefPubMed Tsoutsman T, Bagnall RD, Semsarian C. Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure. Clin Exp Pharmacol Physiol. 2008;35:1349-57.CrossRefPubMed
Zurück zum Zitat Ingles J, Doolan A, Chiu C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;42:e59.CrossRefPubMed Ingles J, Doolan A, Chiu C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;42:e59.CrossRefPubMed
Zurück zum Zitat van Langen IM, Arens Y, Baars H, et al. Concept Multidisciplinaire richtlijn. Genetische diagnostiek en erfelijkheidsadvisering bij Hypertrofische Cardiomyopathie (HCM). Submitted 2009. van Langen IM, Arens Y, Baars H, et al. Concept Multidisciplinaire richtlijn. Genetische diagnostiek en erfelijkheidsadvisering bij Hypertrofische Cardiomyopathie (HCM). Submitted 2009.
Zurück zum Zitat Michels M, Hoedemaekers YM, Kofflard MJ, et al. Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience. Neth Heart J. 2007;15:184-90.CrossRefPubMed Michels M, Hoedemaekers YM, Kofflard MJ, et al. Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience. Neth Heart J. 2007;15:184-90.CrossRefPubMed
Zurück zum Zitat Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol. 2002;17:242-52.CrossRefPubMed Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol. 2002;17:242-52.CrossRefPubMed
Zurück zum Zitat Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:1903-10.CrossRefPubMed Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:1903-10.CrossRefPubMed
Zurück zum Zitat Alpert NR, Mohiddin SA, Tripodi D, et al. Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations. Am J Physiol. 2005;288: H1097-102. Alpert NR, Mohiddin SA, Tripodi D, et al. Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations. Am J Physiol. 2005;288: H1097-102.
Zurück zum Zitat Bos JM, Poley RN, Ny M, et al. Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Gen Metabol 2006;88:78-85.CrossRef Bos JM, Poley RN, Ny M, et al. Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Gen Metabol 2006;88:78-85.CrossRef
Zurück zum Zitat Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-67.PubMed Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-67.PubMed
Zurück zum Zitat Gruver EJ, Fatkin D, Dodds GA, et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His betacardiac myosin heavy chain mutation. Am J Cardiol. 1999;83: 13H-8H.CrossRefPubMed Gruver EJ, Fatkin D, Dodds GA, et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His betacardiac myosin heavy chain mutation. Am J Cardiol. 1999;83: 13H-8H.CrossRefPubMed
Zurück zum Zitat Greber-Platzer S, Marx M, Fleischmann C, et al. Beta-myosin heavy chain gene mutations and hypertrophic cardiomyopathy in Austrian children. J Mol Cell Cardiol. 2001;33:141-8.CrossRefPubMed Greber-Platzer S, Marx M, Fleischmann C, et al. Beta-myosin heavy chain gene mutations and hypertrophic cardiomyopathy in Austrian children. J Mol Cell Cardiol. 2001;33:141-8.CrossRefPubMed
Zurück zum Zitat Song L, Zou Y, Wang J, et al. Mutations profile in Chinese patients with hypertrophic cardiomyopathy. Clin Chim Acta; Int J Clin Chem. 2005;351:209-16.CrossRef Song L, Zou Y, Wang J, et al. Mutations profile in Chinese patients with hypertrophic cardiomyopathy. Clin Chim Acta; Int J Clin Chem. 2005;351:209-16.CrossRef
Zurück zum Zitat Sadoul N, Simon JP, de Chillou C, et al. Dual chamber pacemaker therapy in obstructive hypertrophic cardiomyopathy. Circulation. 1995;92:1062-4.PubMed Sadoul N, Simon JP, de Chillou C, et al. Dual chamber pacemaker therapy in obstructive hypertrophic cardiomyopathy. Circulation. 1995;92:1062-4.PubMed
Zurück zum Zitat Bos JM, Theis JL, Tajik AJ, et al. Relationship between sex, shape, and substrate in hypertrophic cardiomyopathy. Am Heart J. 2008; 155:1128-34.CrossRefPubMed Bos JM, Theis JL, Tajik AJ, et al. Relationship between sex, shape, and substrate in hypertrophic cardiomyopathy. Am Heart J. 2008; 155:1128-34.CrossRefPubMed
Zurück zum Zitat Knoll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 2002;111:943-55.CrossRefPubMed Knoll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 2002;111:943-55.CrossRefPubMed
Zurück zum Zitat Mohapatra B, Jimenez S, Lin JH, et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Gen Metabol. 2003;80:207-15.CrossRef Mohapatra B, Jimenez S, Lin JH, et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Gen Metabol. 2003;80:207-15.CrossRef
Zurück zum Zitat Tsoutsman T, Kelly M, Ng DC, et al. Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy. Circulation. 2008;117:1820-31.CrossRefPubMed Tsoutsman T, Kelly M, Ng DC, et al. Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy. Circulation. 2008;117:1820-31.CrossRefPubMed
Zurück zum Zitat Magga J, Sipola P, Vuolteenaho O, et al. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene. Am J Cardiol. 2008;101:1185-90.CrossRefPubMed Magga J, Sipola P, Vuolteenaho O, et al. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene. Am J Cardiol. 2008;101:1185-90.CrossRefPubMed
Zurück zum Zitat Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part I, MRI appearances. AJR Am J Roentgenol. 2007;189:1335-43.CrossRefPubMed Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part I, MRI appearances. AJR Am J Roentgenol. 2007;189:1335-43.CrossRefPubMed
Zurück zum Zitat Germans T, van Rossum AC. The use of cardiac magnetic resonance imaging to determine the aetiology of left ventricular disease and cardiomyopathy. Heart. 2008;94:510-8.CrossRefPubMed Germans T, van Rossum AC. The use of cardiac magnetic resonance imaging to determine the aetiology of left ventricular disease and cardiomyopathy. Heart. 2008;94:510-8.CrossRefPubMed
Zurück zum Zitat Moon JC, Mogensen J, Elliott PM, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart. 2005;91:1036-40.CrossRefPubMed Moon JC, Mogensen J, Elliott PM, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart. 2005;91:1036-40.CrossRefPubMed
Zurück zum Zitat Germans T, Wilde AA, Dijkmans PA, et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol. 2006;48:2518-2523.CrossRefPubMed Germans T, Wilde AA, Dijkmans PA, et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol. 2006;48:2518-2523.CrossRefPubMed
Metadaten
Titel
Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest double-heterozygosity?
verfasst von
I.A.W. van Rijsingen
J.F. Hermans-van Ast
Y.H.J.M. Arens
S.M. Schalla
C.E.M de Die-Smulders
A. van den Wijngaard
Y.M. Pinto
Publikationsdatum
30.09.2010
Verlag
Bohn Stafleu van Loghum
Erschienen in
Netherlands Heart Journal
Print ISSN: 1568-5888
Elektronische ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-010-0003-2

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.